

**Government of The People's Republic of Bangladesh**  
**Ministry of Health & Family Welfare**  
**Directorate General of Drug Administration**  
**Mohakhali, Dhaka-1212, Bangladesh**  
**www.dgda.gov.bd**

Issue Number: DA/27-37/2001/ ৪৪৬

Dated: 21/04/2024

To : Incepta Pharmaceuticals Ltd.  
Dewan Idris Road, Bara, Rangamatia,  
Zirabo, Ashulia, Savar, Dhaka, Bangladesh

**Subject: Regarding No Objection to importation.**

Ref: IPL/RA/NOC/09/2024; Dated: 17/04/2024

In view of the above subject and reference, no-objection has been granted subject to the following conditions for the exemption from customs department of the medicines listed in the table below.

Proforma Invoice no & date	Supplier name and country	Name of the medicines	Quantity	Country of Origin
2023599 Date: 09.04.2024	Seed Pharma Pty Ltd, Australia	Lorzaar Protect (Losartan Potassium) 50mg tablets by Organon – Germany Pack size: 98's	03 Packs	Germany
		Lorzaar Protect (Losartan Potassium) 100mg tablets by Organon – Germany Pack size: 98's	03 Packs	

Conditions:

1. Medicines cannot be marketed under any circumstances.
2. Medicines is to be used in own factories only for research and development purposes.
3. This no-objection period will be valid for 06 (six) months from the date of issue.



21 APR 2024

**Md. Salahuddin**  
Director

For Director General  
Directorate General of Drug Administration  
&  
Licensing Authority (Drugs)  
Govt. of the People's Republic of Bangladesh  
Phone: 02-2222-80803  
Email: dgda.gov@gmail.com

**Government of The People's Republic of Bangladesh**  
**Ministry of Health & Family Welfare**  
**Directorate General of Drug Administration**  
**Mohakhali, Dhaka-1212, Bangladesh**  
**www.dgda.gov.bd**

Issue Number: DA/27-37/2001/ ২২২

Dated: 21/04/2024

To : Incepta Pharmaceuticals Ltd., Dhamrai Unit  
Head office: 40, Shahid Tajuddin Ahmed Sarani,  
Tejgaon I/A, Dhaka-1208, Bangladesh.

**Subject: Regarding No Objection to importation.**


Ref: IPL/RA/NOC/10/2024; Dated: 17/04/2024

In view of the above subject and reference, no-objection has been granted subject to the following conditions for the exemption from customs department of the medicines listed in the table below.

Proforma Invoice no & date	Supplier name and country	Name of the medicines	Quantity	Country of Origin
15342 Date: 04.03.2024	Amsterdam Pharma, USA	SODIUM BICARBONATE 50MEQ/50ML [SDV-25X50 ML]- EXELA PHARMA SCIENCES LLC Pack size: 25X50ML	03 Packs	USA
		SODIUM BICARBONATE 5MEQ/10ML (0.5MEQ/ML) [SDV-25X10ML]- EXELA PHARMA SCIENCES LLC Pack size: 25X10 ML	06 Packs	
		SODIUM BICARBONATE 50MEQ/50ML [SDV-25X50ML]- PFIZER INC INJECTABLE Pack size: 25X50ML	01 Pack	

Conditions:

1. Medicines cannot be marketed under any circumstances.
2. Medicines is to be used in own factories only for research and development purposes.
3. This no-objection period will be valid for 06 (six) months from the date of issue.

  
**Md. Salahuddin** 21 APR 2024  
Director

For Director General  
Directorate General of Drug Administration  
&  
Licensing Authority (Drugs)  
Govt. of the People's Republic of Bangladesh  
Phone: 02-2222-80803  
Email: dgda.gov@gmail.com

**GOVERNMENT OF THE PEOPLE'S REPUBLIC OF BANGLADESH**  
**MINISTRY OF HEALTH & FAMILY WELFARE**  
**DIRECTORATE GENERAL OF DRUG ADMINISTRATION**  
Mohakhali, Dhaka-1212, BANGLADESH  
[www.dgda.gov.bd](http://www.dgda.gov.bd)

Issue Number: DA/27-37/2001/  $\chi\chi\&$

Dated: 21/04/2024

To : Incepta Pharmaceuticals Ltd.  
Dewan Idris Road, Bara, Rangamatia,  
Zirabo, Ashulia, Savar,  
Dhaka-1341, Bangladesh

Subject: No Objection for sending sample of medicine for registration purpose in Myanmar.

With reference to your letter no. IPL/RA/NOC/11/2024, dated 17th April, 2024 on the above subject this office does not have any objection to issue No Objection Certificate (NOC) for sending the following medicine as sample for registration purpose to Myanmar.

No.	Brand Name	DAR No.	Generic Name	Quantity (Boxes)
1	Orsema 0.25 Injection	116-1469-015	Semaglutide INN	50
2	Orsema 0.5 Injection	116-1470-015	Semaglutide INN	50



21 APR 2024

**Md. Salahuddin**

Director

For Director General

Directorate General of Drug  
Administration

&

Licensing Authority (Drugs)  
Govt. of the People's Republic of  
Bangladesh

Phone: 02-2222-80803

Email: dgda.gov@gmail.com